Stem Cell Transplantation for Sickle Cell Anemia

Primary objective: 1\) To determine disease free survival (DFS) at two years after matched sibling transplant using bone marrow (BM) after a conditioning regimen consisting of distal timed Alemtuzumab, Fludarabine, and Melphalan for patients 2-30 y/o Secondary objectives: 1. Overall survival 2. Rate of neutrophil and platelet engraftment for BM 3. Incidence of graft failure 4. Incidence of grade II-IV and grade III-IV acute graft vs host disease (GVHD) 5. Incidence of chronic GVHD 6. Incidence of other transplant complications, such as veno-occlusive disease, central nervous system (CNS) toxicity, and idiopathic pneumonia syndrome (IPS) 7. Incidence of reactivation of CMV, EBV, adenovirus, BK/JC virus 8. Incidence of invasive fungal disease 9. Time to immune reconstitution via monitoring of lymphocyte subpopulations and immunoglobulin levels